Coronary Sinus Reducer an Option for Intractable Angina?
A coronary sinus reducer met one of two primary endpoints by reducing refractory angina in the ORBITA-COSMIC trial, but not the second, improvement in perfusion.
Source: medscape.com
📰 Ntianginal Agents News
Ntianginal Agents News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Ntianginal Agents. Real-time updates on events, politics, business and more.
Angioplasty Finally Proven Beneficial in Stable Angina
The randomized ORBITA-2 trial, unlike the preceding ORBITA trial, shows benefit for percutaneous coronary intervention in patients with stable angina.
Source: medscape.com
Angioplasty Finally Proven Beneficial in Stable Angina
The randomized ORBITA-2 trial, unlike the preceding ORBITA trial, shows benefit for percutaneous coronary intervention in patients with stable angina.
Source: medscape.com